GSK wagers $2.1B on Affinivax and its next-generation pneumonia vaccine
GSK has agreed to acquire Affinivax in a deal announced Tuesday, betting more than $3 billion that the eight-year-old startup’s technology can lead to a more effectiv...
Continue Reading →
